The book Heat Shock Protein-Based Therapies provides the most up-to-date review on new heat shock protein-based mechanisms used in the therapy and treatment of various human disorders and diseases, including cancer, muscular atrophy, neurodegenerative disorders (Alzheimer's Disease, Multiple Sclerosis) and infectious diseases (HIV, periodontal disease). Written by leaders in the field of heat shock protein research, the chapters systematically and in a step wise fashion takes the reader through the fascinating sequence of events by which mechanisms dependent on heat shock proteins are targeted. The chapters also provide answers as to HSP biological significance to the host. This book is a must read for graduate and postgraduates in the field of Drug Development, Biotechnology, Pharmaceutical Industry, Phytomedicine, Biology (plant and mammal), Biochemistry (pro- and eukaryotic), Oncology, Immunology, Microbiology, Exercise Medicine, Physiology, Inflammatory diseases, Autoimmunity, Pharmacology and Pathology.

This books provides up-to-date reviews on current advances of the role of HSP in veterinary medicine and research. Key basic and clinical research laboratories from major universities, veterinary hospitals and pharmaceutical companies around the world have contributed chapters that review present research activity and importantly project this field into the future. For easy readability, the book is sub divided into sections on HSP in the following aspects of Veterinary Medicine, including, I - Domestic Animals, II - Poultry, III - Aquatic and IV - Parasites. The book is a must read for heat shock protein researchers in general and specifically those involved in clinical and research in veterinary medicine.

Since the advent of hybridoma technology more than two decades ago, numerous antibodies have entered the clinical setting as potent therapeutic agents. Their repeated application in humans, however, is limited by the development of human antimouse antibodies (HAMA) in the recipient, leading to allergic re- tions against the foreign murine protein and rapid neutralization. To circumvent these limitations many new antibodies have recently been tailored through recombinant antibody technology. The initial clinical data show encouraging results, thus demonstrating the potential of these new therapeutic agents. The purpose of Recombinant Antibodies for Cancer Therapy is to present a collection of detailed protocols in recombinant antibody technology. It is pri- rily addressed to scientists working on recombinant antibodies as well as cli- cians involved with antibody-based therapies. As with other volumes of this series, we placed the main focus on providing detailed protocols describing procedures step-by-step. Moreover, each protocol supplies a troubleshooting guide containing detailed information on possible problems and hints for pot- tial solutions. Antibody technology is a subject of constant and rapid change. This volume, therefore, does not attempt to cover all possible current experimental approaches in the field. Rather, we present carefully selected protocols, written by competent authors who have successfully verified the particular method described. Given our own professional backgrounds and interest in oncology, we chose to conc- trate chiefly on therapeutic agents for cancer patients.

This books provides the most up-to-date reviews on current advances in our understanding of the regulation of heat shock protein responses. Key basic scientists and clinical research laboratories from major universities, academic medical centers and pharmaceutical companies around the world have contributed chapters that review present research activity and importantly project this field into the future. For easy readability, the book is sub divided into four sections, including, Section I - HSP and Stress Responses; Section II - Chaperone Functions of HSP; Section III - HSP in Human Diseases; Section IV - Prognosis & Diagnosis of HSP. The book is a must read for researchers involved in biomedical research, drug discovery and design to improve human health.

The book Heat Shock Proteins in Cancer Therapeutics provides the most comprehensive review on contemporary knowledge on the role of HSP in various types of cancer therapeutics. Using an integrative approach, the contributors provide a synopsis of the most current updates on the state of HSP in cancer therapeutics. The heat shock response pathway is a highly conserved cellular process. Heat shock factors are a master transcriptional regulator responsible for expression of several important heat shock proteins, which can effectively protect critical client proteins from misfolding and degradation, thus maintaining intracellular integrity under stressed conditions. Recent studies have demonstrated the direct connections between heat shock response players and tumor cell survival, validating heat shock response players as novel molecular targets in anticancer treatment. Although many hurdles in clinical application still need to be effectively addressed, such as undesirable drug toxicity and off target effects; narrow therapeutic window; poor PK/PD profiles, etc. Recent reports on synergistic drug combination, advanced prodrug design, smart nanoparticle packaging, and RNA aptamer selection offer promising solutions to overcome these challenges. Future advancements in this fast-growing area can potentially lead to the next generation of cancer therapeutics. Key basic and clinical research laboratories from major universities, academic medical hospitals, biotechnology and pharmaceutical laboratories around the world have contributed chapters that review present research activity and importantly project the field into the future. The book is a must read for graduate students. medical students, basic science researchers and postdoctoral scholars in the fields of Cancer Biology, Oncology, Translational Medicine, Clinical Research, Biotechnology, Cell & Molecular Medicine, Pharmaceutical Scientists and Researchers involved in Drug Discovery.

In recent years, biological cancer therapies, including immunotherapy, have moved from the bench to mainstream medical treatments of several types of cancer. The success of these treatments relies on innovative approaches to specifically interfere with molecular targets that are involved in the growth, progression, and spread of malignant cells, or to bypass the tumor evasion of the immune system utilizing the latest advances in cancer vaccine development, formulation, and delivery. This book presents an up-to-date overview of novel cancer biological and immunotherapeutic approaches, including cancer vaccines, mimetic vaccines, monoclonal antibodies, adoptive T-cell transfer, chimeric antigen receptor T- cells, tumor infiltrating lymphocytes, dendritic cells, natural killer cells, immune checkpoint inhibitors, laser ablation, and immune stimulating interstitial laser thermotherapy.

Published in 1997: Antibody Therapeutics is a comprehensive evaluation of progress toward using humanized antibodies as a new generation of therapeutics. The humanized antibodies that have led the way in product approval are discussed as case studies, offering an insight into the preclinical and clinical data acquired during the regulatory approval process. Leading experts offer their findings as examples of what works and what does not, saving you time and making your research more cost effective. This book is essential reading for researchers, clinicians, development and regulatory staff in pharmaceutical and biotechnology companies, and hospital staff, including policy and decision makers. It also provides postgraduate and medical students with an authoritative overview of the field.

Harnessing the potential of the human body's own immune system to attack malignant tumor cells has been the goal of many scientific investigators in recent years, with advances in cancer biology and immunology enabling cancer immunotherapy to become a reality. World-class bench and clinical researchers have joined forces to collaborate and review current developments and trends in cancer immunology for the purposes of this book, and the result is a promising review of contemporary clinical treatments. In each chapter the authors present the scientific basis behind such therapeutic approaches, including cancer vaccines with special focus on prostate cancer, melanoma and novel approaches utilizing both innate and adaptive immune responses.

Kidney cancer is a heterogenous disease. This book covers: -new surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques; -new staging and prognostic capabilities; -evolving therapeutic options include, cell based vaccine, gene and antibody therapy; -molecular genetics allow for a better understanding of the various types of kidney cancer. Kidney Cancer is a comprehensive review covering present and future surgical approaches, staging and prognostic factors, currently accepted and future plans for prevention, diagnosis and treatment. Contributing authors to this book are internationally recognized specialists in this disease. This book will be useful to the specialist (oncologist and urologist), primary care physicians, patients and family members dealing with kidney cancer.